SGMT
$5.19
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States.
Recent News
Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf.
Sagimet Biosciences (NASDAQ:SGMT) used an investor discussion at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference to outline its strategy around fatty acid synthase (FASN) inhibition, with development efforts centered on metabolic dysfunction-associated steatohepatitis (MASH), acne, and
Sagimet Biosciences Showcases FASN Strategy, MASH Phase II Timeline and Acne Data at Guggenheim Conference
Sagimet Biosciences (NASDAQ:SGMT) used a presentation at Guggenheim’s Emerging Outlook Conference to highlight its strategy of targeting fatty acid synthase (FASN) across metabolic and dermatologic indications, and to outline upcoming clinical milestones and cash runway. Focus on FASN inhibition ac
A Look At Sagimet Biosciences (SGMT) Valuation After Denifanstat’s Phase 3 Acne Trial Success
Sagimet Biosciences (SGMT) drew fresh attention after reporting that Denifanstat met all primary and secondary endpoints with a favorable safety profile in a Phase 3 acne trial, underscoring progress for its FASN inhibitor approach. See our latest analysis for Sagimet Biosciences. The latest Denifanstat acne data arrives after a mixed stretch for the stock, with a 9.75% 1 month share price return and a 20.94% decline over 3 months, yet a 1 year total shareholder return of 18.52%. This hints...
After Clearing Up Acne, Sagimet Stock Rises
Shares of Sagimet Biosciences were up as much as 12% after encouraging clinical trial results for its acne treatment.
Adobe downgraded, Palantir upgraded: Wall Street's top analyst calls
Adobe downgraded, Palantir upgraded: Wall Street's top analyst calls